Compare Inovio Pharmaceuticals Inc (INO) vs IQIYI Inc - ADR (IQ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Inovio Pharmaceuticals Inc vs IQIYI Inc - ADR — how do they compare? Inovio Pharmaceuticals Inc trades at $0.76 (market cap $78.55M), while IQIYI Inc - ADR trades at $1.33 (market cap $1.30B). The key difference: IQIYI Inc - ADR is far larger — about 16.5× Inovio Pharmaceuticals Inc's market cap, and IQIYI Inc - ADR is trading nearer its 52-week high, Inovio Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| INO | IQ | |
|---|---|---|
Market Cap | $78.55M | $1.30B |
Sector | Health | Media |
52-Week High | $2.87 | $2.79 |
52-Week Low | $0.66 | $0.96 |
Enterprise Value | $49.56M | $2.88B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INO trades at $0.772, up 4.83% in the last 24 hours, but technical indicators signal a bearish trend. The company shows minimal revenue of $65,340 in 2025 with a net loss of $84.95 million, though it has beaten EPS estimates in recent quarters. Key developments include an upcoming Q2 2026 earnings report on August 12, 2026, and a pending FDA decision on INO-3107 by October 30, 2026.
The outlook hinges on FDA approval of INO-3107, with a consensus price target of $3.25 implying significant upside. However, high cash burn, negative margins, and legal scrutiny pose substantial risks. Investors should weigh the binary event against persistent financial challenges.
IQ trades at $1.325, down 2.57% in 24 hours, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of $206.31 million in 2025, with revenue declining to $27.29 billion, though it beat EPS expectations in two recent quarters. Analyst sentiment is mixed with a 50% buy rating, while news highlights AI platform growth and leadership changes as potential catalysts.
The outlook hinges on IQ's AI-driven content strategy and cost management reversing profitability declines. Risks include intense competition, regulatory pressures in China, and sustained negative cash flow projections for 2026. Upside potential exists if execution improves, but high debt and margin pressures warrant caution for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →About IQIYI Inc - ADR
iQIYI Inc is an online entertainment service provider in China. It is primarily engaged in providing a variety of services encompassing internet video, live broadcasting, online games, online literature, animations, e-commerce, and social media platform. The company produces original video content and distributes appealing professionally produced content, partner-generated content, and user-generated content. It also offers a diverse collection of internet video content that appeals to users from broad demographics. The company's revenue is generated from membership services and online advertising services. The company earns most of its revenue from China.
Read more on IQ →
